236 related articles for article (PubMed ID: 27411166)
1. Metabotropic glutamate receptor 5 responses dictate differentiation of neural progenitors to NMDA-responsive cells in fragile X syndrome.
Achuta VS; Grym H; Putkonen N; Louhivuori V; Kärkkäinen V; Koistinaho J; Roybon L; Castrén ML
Dev Neurobiol; 2017 Apr; 77(4):438-453. PubMed ID: 27411166
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.
Lea PM; Movsesyan VA; Faden AI
Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750
[TBL] [Abstract][Full Text] [Related]
3. In vivo metabotropic glutamate receptor 5 (mGluR5) antagonism prevents cocaine-induced disruption of postsynaptically maintained mGluR5-dependent long-term depression.
Grueter BA; McElligott ZA; Robison AJ; Mathews GC; Winder DG
J Neurosci; 2008 Sep; 28(37):9261-70. PubMed ID: 18784306
[TBL] [Abstract][Full Text] [Related]
4. mGluR5 promotes the differentiation of rat neural progenitor cells into cholinergic neurons and activation of extracellular signal-related protein kinases.
Zhao L; Jiao Q; Huang C; Hou N; Chen X; Zhang J; Yang P; Xu X; Song T; Liu Y
Neuroreport; 2014 Apr; 25(6):427-34. PubMed ID: 24670535
[TBL] [Abstract][Full Text] [Related]
5. Selective induction of metabotropic glutamate receptor 1- and metabotropic glutamate receptor 5-dependent chemical long-term potentiation at oriens/alveus interneuron synapses of mouse hippocampus.
Le Vasseur M; Ran I; Lacaille JC
Neuroscience; 2008 Jan; 151(1):28-42. PubMed ID: 18035501
[TBL] [Abstract][Full Text] [Related]
6. Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome.
Careaga M; Noyon T; Basuta K; Van de Water J; Tassone F; Hagerman RJ; Ashwood P
J Neuroinflammation; 2014 Jun; 11():110. PubMed ID: 24942544
[TBL] [Abstract][Full Text] [Related]
7. BDNF in fragile X syndrome.
Castrén ML; Castrén E
Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
[TBL] [Abstract][Full Text] [Related]
8. Functional changes of AMPA responses in human induced pluripotent stem cell-derived neural progenitors in fragile X syndrome.
Achuta VS; Möykkynen T; Peteri UK; Turconi G; Rivera C; Keinänen K; Castrén ML
Sci Signal; 2018 Jan; 11(513):. PubMed ID: 29339535
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic mGluR5 receptor controls glutamatergic input through protein kinase C-NMDA receptors in paclitaxel-induced neuropathic pain.
Xie JD; Chen SR; Pan HL
J Biol Chem; 2017 Dec; 292(50):20644-20654. PubMed ID: 29074619
[TBL] [Abstract][Full Text] [Related]
10. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors.
Movsesyan VA; O'Leary DM; Fan L; Bao W; Mullins PG; Knoblach SM; Faden AI
J Pharmacol Exp Ther; 2001 Jan; 296(1):41-7. PubMed ID: 11123360
[TBL] [Abstract][Full Text] [Related]
11. Interactions between ionotropic and metabotropic glutamate receptors regulate cAMP response element-binding protein phosphorylation in cultured striatal neurons.
Mao L; Wang JQ
Neuroscience; 2002; 115(2):395-402. PubMed ID: 12421605
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated NMDA-Receptor Signaling Inhibits Long-Term Depression in a Mouse Model of Fragile X Syndrome.
Toft AK; Lundbye CJ; Banke TG
J Neurosci; 2016 Sep; 36(38):9817-27. PubMed ID: 27656021
[TBL] [Abstract][Full Text] [Related]
13. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism.
O'Leary DM; Movsesyan V; Vicini S; Faden AI
Br J Pharmacol; 2000 Dec; 131(7):1429-37. PubMed ID: 11090117
[TBL] [Abstract][Full Text] [Related]
14. Involvement of metabotropic glutamate receptor 5 signaling in activity-related proliferation of adult hippocampal neural stem cells.
Nochi R; Kato T; Kaneko J; Itou Y; Kuribayashi H; Fukuda S; Terazono Y; Matani A; Kanatani S; Nakajima K; Hisatsune T
Eur J Neurosci; 2012 Aug; 36(3):2273-83. PubMed ID: 22591399
[TBL] [Abstract][Full Text] [Related]
15. Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.
Fish EW; Krouse MC; Stringfield SJ; Diberto JF; Robinson JE; Malanga CJ
PLoS One; 2013; 8(10):e77896. PubMed ID: 24205018
[TBL] [Abstract][Full Text] [Related]
16. mGlu5R promotes glutamate AMPA receptor phosphorylation via activation of PKA/DARPP-32 signaling in striatopallidal medium spiny neurons.
Dell'anno MT; Pallottino S; Fisone G
Neuropharmacology; 2013 Mar; 66():179-86. PubMed ID: 22507666
[TBL] [Abstract][Full Text] [Related]
17. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.
Su T; Fan HX; Jiang T; Sun WW; Den WY; Gao MM; Chen SQ; Zhao QH; Yi YH
Psychopharmacology (Berl); 2011 May; 215(2):291-300. PubMed ID: 21181121
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice.
Kozela E; Pilc A; Popik P
Psychopharmacology (Berl); 2003 Jan; 165(3):245-51. PubMed ID: 12442203
[TBL] [Abstract][Full Text] [Related]
19. Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders.
Burket JA; Herndon AL; Winebarger EE; Jacome LF; Deutsch SI
Brain Res Bull; 2011 Oct; 86(3-4):152-8. PubMed ID: 21840381
[TBL] [Abstract][Full Text] [Related]
20. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia.
Bao WL; Williams AJ; Faden AI; Tortella FC
Brain Res; 2001 Dec; 922(2):173-9. PubMed ID: 11743947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
